Inovio announces promising interim results from ongoing proof-of-concept clinical trial of dna-encoded monoclonal antibodies (dmabs) for covid-19

Long-lasting in vivo antibody production: dmab levels remained stable for 72 weeks in all participants (n=24) who have reached that timepoint no anti-drug antibodies (ada): no immune rejection of the dmabs was detected across ~1,000 blood samples, unlike other gene-based antibody delivery approaches where ada formation has been a challenge well-tolerated: most common side effects were mild, temporary injection site reactions such as pain and redness; no serious adverse events (saes) related to study drug effective target binding: expressed dmabs successfully bound to the sars-cov-2 spike protein receptor-binding domain (rbd), confirming functional activity through week 72 plymouth meeting, pa. , march 13, 2025 /prnewswire/ -- inovio (nasdaq: ino), a biotechnology company focused on developing and commercializing dna medicines to help treat and protect people from hpv-related diseases, cancer, and infectious diseases, today announced promising interim results from an ongoing phase 1 proof-of-concept trial evaluating dmabs for covid-19.
DNA Ratings Summary
DNA Quant Ranking